Inclusion Criteria:

- Age > 60 and < 80 years

- Non eligible for stem cell transplantation

- CD20 diffuse large B-cell lymphoma according to the WHO classification

- Bulky stage I and II > ou =7 cm and stage III and IV

- Performance status 0 - 2

- Creatinine clearance >ou = 50 ml/min (Cockroft formula).

- Serum bilirubin < ou =30 mmol/l

- Leucocytes > ou =3 G/l, granulocytes > ou = 1,5 G/l, platelets >ou= 100 G/L.

- HIV negative

- Written informed consent

Exclusion Criteria:

- Age < 60 years and > 80 years

- Other types of lymphomas except CD20+ diffuse large B-cell lymphoma according to the
WHO classification

- Histologic transformation of low grade lymphoma (Involvement of the bone marrow by
small B-cell lymphoma will not lead to exclusion of the patient)

- Primary lymphoma of the central nervous system and transformed gastro intestinal MALT
lymphoma

- Meningeal involvement

- Bone marrow involvement > 25% after R-CHOP

- Aggressive post-transplantation lymphoma

- Absence of CD20 expression on tumor cells

- Non bulky stages I et II

- HIV positive

- Active Hepatitis B or C

- Left ventricular ejection fraction < 50%.

- Contra-indication to R-CHOP treatment

- Previous or concurrent second malignancy except for adequately treated basal cell
carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively
treated solid cancer, with no evidence of disease for at least 5 years

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule

- Participation at the same time in another study in which investigational drugs are
used

- Absence of written informed consent